Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
Figure 2
A 52-year-old male patient had been treated with surgery and postoperative adjuvant chemotherapy for sigmoid colon cancer (adenocarcinoma, T2N2M0). 13 months later, liver metastasis developed and he was then treated with salvage chemotherapy; however, follow-up CT scan after the chemotherapy showed progression of liver metastasis (white arrows) (a). We decided to treat him with SABR. The prescriptive dose to the planning target volume including two metastatic tumor lesions was 40 Gy in 4 fractions on consecutive day (b). The CT scan on 3 months after the completion of SABR showed complete response (c). Radiotherapy related change of increased density around the previous tumor lesions was shown but the patient’s liver function test was normal.
